These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26310004)

  • 21. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
    Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
    Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
    Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
    Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab.
    Calvo P; Ferreras A; Al Adel F; Wang Y; Brent MH
    Br J Ophthalmol; 2015 Jun; 99(6):723-6. PubMed ID: 25425713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration.
    Demirel S; Batioğlu F; Özmert E; Erenler F
    Curr Eye Res; 2015 Jan; 40(1):87-92. PubMed ID: 24871814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks.
    Lushchyk T; Amarakoon S; Martinez-Ciriano JP; van den Born LI; Baarsma GS; Missotten T
    Acta Ophthalmol; 2013 Sep; 91(6):e456-61. PubMed ID: 23773796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Ciulla TA; Ying GS; Maguire MG; Martin DF; Jaffe GJ; Grunwald JE; Daniel E; Toth CA;
    Ophthalmology; 2015 Jun; 122(6):1203-11. PubMed ID: 25824327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
    Gomi F; Sawa M; Tsujikawa M; Nishida K
    Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
    Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
    Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
    Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
    Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab.
    Wolf A; Rüping J; Neubauer AS; Mayer W; Ulbig M; Haritoglou C; Holz FG; Eter N; Kampik A
    Retina; 2013 Oct; 33(9):1843-9. PubMed ID: 23598795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
    Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
    Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
    Good TJ; Kimura AE; Mandava N; Kahook MY
    Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP; Haji SA; Frenkel RE
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.